Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:53 AM
Ignite Modification Date:
2025-12-25 @ 3:53 AM
NCT ID:
NCT00009802
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Histologically proven advanced cancer not curable by standard therapies
* Brain metastases allowed following definitive radiotherapy
PATIENT CHARACTERISTICS:
Age:
* 18 and over
Performance status:
* ECOG 0-2
Life expectancy:
* Not specified
Hematopoietic:
* Absolute neutrophil count at least 1,500/mm\^3
* Platelet count at least 100,000/mm\^3
Hepatic:
* Bilirubin no greater than 1.5 mg/dL
* SGOT no greater than 4 times normal
Renal:
* Creatinine no greater than 2.0 mg/dL
* Calcium no greater than 10.5 mg/dL
Other:
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective double-barrier contraception for at least 1 week before, during, and for at least 2 weeks after study
* No active infection or serious concurrent condition
* No symptomatic peripheral neuropathy greater than grade 1
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* At least 3 weeks since prior regional or systemic biologic therapy
Chemotherapy:
* At least 3 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosourea)
Endocrine therapy:
* Not specified
Radiotherapy:
* See Disease Characteristics
* At least 3 weeks since prior radiotherapy
Surgery:
* Not specified
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00009802
Study Brief:
Protocol Section:
NCT00009802